100 results about "SUBCUTANEOUS TUMOR" patented technology

The invention belongs to the technical field of microbial medicine, and provides a primary multidrug resistance human far-end bile duct cancer cell line CBC3T-6 Homo sapiens and application thereof.The human far-end bile duct cancer cell line CBC3T-6 Homo sapiens is separated from differentiated adenocarcinoma in a far-end bile duct, the human far-end bile duct cancer cell line CBC3T-6 Homo sapiens is already subcultured to 50 generations at present, the long-term in-vitro culture character is stable, and on the premise that the biological characteristics of bile duct cancer are reserved, the human far-end bile duct cancer cell line CBC3T-6 Homo sapiens can be used for preparing the primary multidrug resistance human far-end bile duct cancer cell line CBC3T-6 Homo sapiens. The compound has the characteristics of short multiplication time, high mouse subcutaneous tumor formation rate and the like, and has different degrees of drug resistance to gemcitabine, 5-fluorouracil, oxaliplatin and cis-platinum in first-line anti-cancer drugs for bile duct cancer. The method not only enriches an extrahepatic bile duct cancer cell bank, provides a new cell model for basic research and clinical drug research and development of bile duct cancer, but also provides powerful scientific research data for research developed based on the genetic background of Chinese population. Therefore, the primary multidrug resistant cell line has higher scientific research and clinical application values.

The invention relates to application of a retinoic acid compound in preparation of a medicine for treating and / or preventing glioblastoma. Compared with the prior art, the retinoic acid compound (1uM, 5uM) group has the advantages that the tumor inhibition rate of a glioblastoma organ is higher than that of an apatinib (1uM, 5uM) group, and is higher than that of an apatinib (1uM, 5uM) group. The subcutaneous tumor inhibition rate of glioblastoma cells of a retinoic acid compound (0.5 mg / kg and 5mg / kg) group is higher than that of an apatinib (32.5 mg / kg) group, and is higher than that of the apatinib (32.5 mg / kg) group in tumor pathological blood vessel inhibition rate. Therefore, the medicine (retinoic acid compound) for treating and (or) preventing the glioblastoma has a remarkable treatment and (or) preventing effect on the glioblastoma.

The invention provides a multifunctional self-bionic nano vaccine for treating breast cancer. The multifunctional self-bionic nano vaccine comprises MnOx nano particles serving as inner cores and fusion cell membranes wrapping the surfaces of the inner cores of the MnOx nano particles, the fused cell membrane is obtained by fusing a remodeled 4T1 cell membrane and a remodeled DC cell membrane. According to the invention, the nano vaccine can play an immunotherapy role in treating breast cancer under the condition of subcutaneous injection. After subcutaneous peritumoral injection, the multifunctional autologous bionic nano vaccine can target tumor tissues to play an in-situ chemical power treatment role, chemotactic to drainage lymph nodes to realize efficient T cell immune response to play an immunotherapy role, and main organs of the whole body are less gathered, so that the vaccine is safe and reliable; the SPNE prepared in the prior art can cause a certain liver aggregation effect after intravenous injection, and great toxic and side effects are generated.

The invention discloses application of annular RNACirc3426 as a diagnostic marker and a therapeutic target of colorectal cancer. Experiments show that the Circ3426 is highly expressed in colorectal cancer cells and patient serum, and prove that the Circ3426 has good stability, and an ROC curve shows that the Circ3426 has good capacity of diagnosing colorectal cancer. Meanwhile, it is found that the molecule can promote migration and invasion ability of colorectal cancer cells, nude mouse subcutaneous tumor formation experiments prove that knock-down Circ3426 inhibits growth of tumors, and it is indicated that the molecule can serve as a treatment target of colorectal cancer. The invention provides a new diagnostic marker and a treatment target for colorectal cancer, and provides a new thought and direction for CRC diagnosis and treatment.

The invention relates to the technical field of biological medicines, in particular to a CKAP4-targeted tumor antigen peptide, a vaccine and application of the CKAP4-targeted tumor antigen peptide. The invention provides a high-immunogenicity tumor antigen peptide RLTELTKSI targeting human and mouse homologous CKAP4 protein, and the tumor antigen peptide and a vaccine thereof can realize efficient killing of CKAP4 positive tumor cells and remarkable inhibition of CT26 subcutaneous tumor by activating specific CD8 + T cell immune response. The traditional single-target limitation is broken through, the co-expression characteristic of CKAP4 in tumor cells and immunosuppressive cells (TAM / TAN) is utilized, a double-target and double-channel mechanism is initiated, and the immunosuppressive state of cold tumors is effectively reversed by inducing T cells to synchronously kill tumor cells and remodel an immune microenvironment. According to the technology, CKAP4 is expanded from an antibody target to a T cell vaccine target, lasting specific CTL response can be stimulated, the off-target risk of antibody treatment is avoided, a universal treatment scheme can be provided for solid tumors, and the clinical transformation potential and the treatment broad spectrum are remarkably improved.

The invention discloses application of lncRNASEH1-AS1 as a target in preparation of a medicine for treating lung squamous cell carcinoma, and belongs to the technical field of biological medicine. The invention finds that the expression of the lncRNASEH1-AS1 in tissues, plasma and cell lines of a lung squamous cell carcinoma patient is higher than that of a control group of the lung squamous cell carcinoma patient. The lncRNASEH1-AS1 has clinical correlation with the tumor diameter of a lung squamous cell carcinoma patient. The results of CCK-8, clone formation, Transwell migration and invasion experiments show that after the lncRNASEH1-AS1 and the MCM7 are knocked down, the proliferation, migration and invasion ability of the lung squamous cell carcinoma cells is weakened, and after the lncRNASEH1-AS1 is over-expressed, the inhibition of the MCM7 on the proliferation, migration and invasion ability of the lung squamous cell carcinoma cells can be reversely knocked down. The result of a nude mouse subcutaneous tumor formation experiment shows that the tumor formation capability of the LUSC cells which stably knock down the lncRNASEH1-AS1 is weakened.

The invention relates to the technical field of medicines, and discloses a bifidobacterium longum strain GZBAI 01 and application thereof in degradation of benzoic acid and prevention or treatment of colorectal cancer. The strain is separated from faeces of healthy people, genomics identification is carried out, the metabolic profile of the strain is measured through metabonomics, the strain can convert benzoic acid with carcinogenic risk into protocatechuic acid with antitumor activity through unique metabolic capability, meanwhile, the function of regulatory T cells (Treg) in tumor drainage lymph nodes can be inhibited, differentiation of CD8 + T cells is promoted, and the tumor drainage lymph nodes can be inhibited. Therefore, the colorectal cancer is prevented through double ways of eliminating cancerogen and generating therapeutic agents. A colorectal cancer mouse model and a subcutaneous tumor mouse model verify that the strain can significantly reduce the number and volume of tumors, and shows a benzoic acid conversion effect superior to that of other strains in vivo and in vitro, and a new way is provided for prevention and treatment of colorectal cancer.

The invention belongs to the technical field of biological medicine, and relates to a kidney cancer axitinib drug-resistant cell model and a construction method and application thereof. The technical problems that in the prior art, a kidney cancer axitinib drug resistance mechanism is not clear, and a drug resistance target of the mechanism and a cell model of a molecular mechanism are lacked for research are solved. The invention provides a construction method of a kidney cancer axitinib drug-resistant cell model. The construction method comprises the following steps: constructing a nude mouse subcutaneous tumor-bearing model by using a kidney cancer cell line; when a subcutaneous tumor of a nude mouse reaches a target volume, after axitinib gavage treatment is performed on the nude mouse, first-generation drug-resistant kidney cancer cells are obtained through separation; shearing the tumor blocks into tumor blocks, inoculating the tumor blocks to the armpits of nude mice, and repeating the steps of gavage, separation and inoculation to respectively obtain second-generation and third-generation drug-resistant kidney cancer cells; and cutting the third-generation drug-resistant kidney cancer cells into pieces, digesting and culturing to obtain the kidney cancer axitinib drug-resistant cell model. The constructed kidney cancer axitinib drug-resistant cell model is applied to research of a kidney cancer cell targeted therapy drug-resistant mechanism and screening or preparation of kidney cancer targeted drugs.

The invention relates to application of lactobacillus muricatum in preparation of a medicine for treating oral cancer, the oral cancer is oral squamous cell carcinoma, a C57BL / 6 mouse tongue squamous cell carcinoma model induced by a 4-NQO water drinking method and a C3H / HeN subcutaneous tumor model inoculated by SCC7 tumor cells are constructed, and the lactobacillus muricatum has a remarkable inhibition effect on the oral cancer; experiments prove that the number / area / volume / weight of tumors is remarkably reduced by the lactobacillus muricatum, tumor marginal infiltration and abnormal karyokinesis are effectively inhibited, the expression quantity of tumor proliferation markers is remarkably reduced, and obvious pathological changes do not appear in main organs (heart, liver, spleen, lung and kidney) of mice. The method for minimally invasive injection of the lactobacillus muricatum into the oral squamous cell cancer tumor is safe, drug resistance is not easily induced, the treatment scheme is standardized, and the method has good clinical application potential.

The present invention belongs to the field of bioengineering technology, in particular to a HPV16 / 18 therapeutic vaccine, preparation method and application. The present invention discloses a fusion protein, which is a protein as follows a) or b): a) the amino acid sequence is a fusion protein of SEQ ID No.2; b) the amino acid sequence shown in SEQ ID No.2 is replaced and / or deleted and / or added to obtain a fusion protein with HPV16 / 18E6-E7 activity. The recombinant adenovirus that can express the fusion protein HPV16 / 18E7 protein provided by the present invention is used as an HPV16 / 18 therapeutic vaccine (MATV3), which has good immunogenicity in a mouse model and can induce a strong cellular immune response in a short time. The study on the tumor inhibition effect of the TC-1 mouse subcutaneous tumor model showed that the growth of TC-1 tumors can be significantly inhibited after two inoculations of MATV3, and HPV 16E7 and HPV18E7-specific cellular immune responses can be generated in mice. The vaccine preparation method is fast and simple, and can be mass-produced for community populations.

The present invention relates to the field of biomedicine technology, and specifically discloses an anti-tumor antigen BAP31 monoclonal antibody, a Cy5-BAP31 directly labeled monoclonal antibody and its application. The monoclonal antibody includes a heavy chain variable region and a light chain variable region. The nucleotide sequence of the heavy chain variable region of the monoclonal antibody is shown in SEQ ID NO.1, and its amino acid sequence is shown in SEQ ID NO.3. The nucleotide sequence of the light chain variable region of the monoclonal antibody is shown in SEQ ID NO.2, and its amino acid sequence is shown in SEQ ID NO.4. The anti-BAP31 monoclonal antibody provided by the present invention can specifically recognize the BAP31 molecule, inhibit the subcutaneous tumor formation ability and in vivo metastasis ability of liver cancer cells, and significantly prolong the survival of tumor-bearing nude mice.

Phytol (PHY) is a metabolite of plant chlorophyll, is wide in source and is a chain-like diterpenoid substance consisting of four isoprene units, and the phytol ingested by animals is subjected to oxidative metabolism in vivo, so that not only can energy be provided for the animals, but also the growth of the animals can be promoted, and the growth of the animals can be promoted. Moreover, the phytol and the phytanic acid metabolite of the phytol can also be used as signal molecules to participate in glycolipid metabolism and adipocyte differentiation regulation processes, but people cannot directly take the phytol and the phytanic acid from the nature. The effect of phytol in the generation and development of tumors still has huge unknown property. According to the research, the influence of the phytol and the derivative thereof on the growth of colon cancer, breast cancer and melanoma is detected through an in-vitro experiment CCK-8 (Cell Count Kit 8) and an in-vivo experiment such as a mouse subcutaneous tumor model, and the phytol and the derivative thereof are found to be capable of remarkably inhibiting the growth of colon cancer, breast cancer and melanoma and have no obvious toxic and side effects on heart, liver and kidney functions.

The present application relates to the application of Hhex agonists in promoting anti-tumor immunity. Specifically, the present application provides a pharmaceutical composition comprising chenodeoxycholic acid and an anti-PD-1 antibody. The present application also provides the use of chenodeoxycholic acid and an anti-PD-1 antibody in the preparation of a drug for promoting anti-tumor immunity. In addition, the present application also provides the use of chenodeoxycholic acid and an anti-PD-1 antibody in the preparation of a drug for treating tumors. The present application uses chenodeoxycholic acid to improve the tumor immune microenvironment and uses it to treat subcutaneous tumors, further verifying that the application of chenodeoxycholic acid can improve the tumor immune microenvironment.

The application discloses a nano-antibody (also known as single-domain antibody) conjugated photosensitizer targeting HER2, a preparation method of the photosensitizer and application of the photosensitizer in tumor photodynamic therapy. The photosensitizer is shown in a general formula (I). In the photosensitizer, the nano-antibody (N HER2 ) serving as a targeting ligand is connected with a photosensitive moiety (PS) through a catalytic reaction mediated by a transglutaminase (MTGase). Research finds that the anti-HER2 nano-antibody conjugated photosensitizer molecule has good cell killing selectivity and tumor enrichment capacity, and can remove a subcutaneous tumor of a mouse with high HER2 expression in one administration. HER2 -PEG 1K -PS (I).

The invention provides an anti-tumor combined treatment method for improving a radiotherapy curative effect by using nintedanib, and relates to the technical field of tumor treatment. The anti-tumor combined treatment method comprises the following steps: selecting a male mouse or a male nude mouse as an experimental animal, and subcutaneously constructing a tumor-bearing mouse model on the back of the experimental animal; when the tumor volume of the tumor-bearing mice reaches 70-100mm < 3 >, randomly dividing the tumor-bearing mice into four groups, namely a control group, a nintedanib single drug group, a radiotherapy group and a combined group; measuring the subcutaneous tumor volume and weight of the tumor-bearing mouse every three days; drawing a mouse tumor growth curve, a mouse survival curve and a mouse weight change curve according to the measured data; a tumor-bearing mouse is subjected to living body imaging, tumor tissue paraffin embedding, immunohistochemical staining, TUNEL staining and Hamp; and E, carrying out section staining and blood biochemical detection, and carrying out data analysis by utilizing corresponding analysis software, so as to evaluate the anti-tumor effect and safety of the combined treatment. According to the invention, tumor growth can be effectively inhibited.

The invention belongs to the technical field of tumor vaccine development, and particularly relates to a tumor cell vaccine of gene knockout MSH2 as well as a preparation method and application of the tumor cell vaccine. Aiming at the problems that the immunogenicity of pMMR tumor cells is low and the tumor cell vaccine prepared from the pMMR tumor cells is difficult to activate an organism to generate effective anti-tumor immunity, the invention provides a cell vaccine of gene knockout MSH2 as well as a preparation method and application of the cell vaccine. The invention discovers that the immunotherapy effect of the tumor cell vaccine can be improved by knocking out the MSH2 for the first time, and proves that the MSH2 can be used as a new transformation target of the tumor cell vaccine. The vaccine is prepared from MSH2 gene knockout tumor cells through irradiation inactivation, it is found that the vaccine can remarkably inhibit growth of far-end subcutaneous tumors and AOM + DSS induced primary colorectal cancer tumors, meanwhile, long-term broad-spectrum anti-tumor immune memory can be induced, and growth of heterogeneous tumor cells is effectively inhibited. In conclusion, the invention has potential significance in clinical application of broad-spectrum tumor cell vaccines.

The present invention discloses that cancer cells secrete succinate into extracellular milieu, which increases macrophage migration and mediates TAM polarization. Furthermore, succinate induces cancer cell EMT, enhances cancer cell migration, and promotes cancer metastasis in murine models. It is indicated in the present invention that serum succinate concentration is elevated in patients with lung cancer when compared to healthy subjects. It implies that during cancer development and progression, cancer cells release a large quantity of succinate into the circulation. As shown in the present invention, serum succinate has a high discriminatory power, it represents a new class of circulating oncometabolite with potential value for predicting NSCLC. Furthermore, as elevation of succinate level in LLC tumor model is accompanied by increased TAMs in the subcutaneous tumors and enhanced cancer metastasis, serum succinate may be a useful therapeutic biomarker for NSCLC treatment. The present invention also provides an anti-succinate antibody that can serve as a cancer therapeutic agent.

The application provides a kind of intracellular near-infrared light catalysis nano-assembly and preparation method and application, the nano-assembly of the application involves three components, one is the photocatalyst with near-infrared absorption, simultaneously as photothermal reagent, two is NO release base element, three is amphiphilic block copolymer polyethylene glycol block polycaprolactone.By fast nano precipitation method, amphiphilic block copolymer is self-assembled in aqueous solution to load photocatalyst and NO release base element, obtain nano-assembly, the photocatalyst molecule in the nano-assembly can be used as photo-oxidation and reduction catalyst under light condition to activate NO donor molecule to release NO, can also consume intracellular NADH, can also produce heat, can effectively kill triple-negative breast cancer tumor cells, and effectively inhibit tumor growth in mouse subcutaneous tumor model.

The invention discloses a saikoside D self-assembled nano-drug as well as a preparation method and application thereof, saikoside D is self-assembled to form the saikoside D nano-drug (SSD-NPs), and the prepared SSD-NPs has remarkable anti-cancer activity. An in-vitro experiment shows that the SSD-NPs can be used for remarkably inhibiting the activity of HCT-116 and HT-29 colon cancer cells. In addition, the SSD-NPs can also inhibit the cell activity of the hepatoma carcinoma cell Hepg2. Then, an HCT-116 colorectal cancer cell line is taken as an example, the anticancer efficacy of the SSD-NPs is verified in a subcutaneous tumor-bearing mouse model, and the SSD-NPs shows a remarkable anti-colorectal cancer effect in the aspect of improving the size and volume of a subcutaneous tumor-bearing of a CRC mouse. Therefore, the saikoside D nano-drug (SSD-NPs) provided by the invention provides a new candidate compound for cancer treatment.

This invention belongs to the field of tumor biology and drug screening technology, specifically disclosing a human EGFR mutation-driven mouse primary lung cancer cell line, its construction method, and its applications. The cell line, ZST-1, is a human EGFR (L858R / T790M) mutation-driven lung cancer cell line derived from mouse primary lung cancer. It is stable, capable of subcutaneous tumor formation in C57BL / 6 mice, and simultaneously expresses Luciferase and tdTomato reporter genes. Its construction method includes obtaining transgenic mice, virus-induced tumor formation, continuous in vivo passage in nude mice, and in vitro culture and screening steps. This cell line can be applied to in vitro screening and efficacy evaluation of human EGFR mutation-targeting drugs, research on EGFR-TKI resistance mechanisms, tumor bioluminescence imaging and fluorescence tracing, and in vivo tumorigenesis and efficacy experiments in an immune-intact C57BL / 6 background.

The invention discloses a human small cell lung cancer cell line and application thereof, the human small cell lung cancer cell line is preserved in China Center for Type Culture Collection, and the preservation number of the human small cell lung cancer cell line is CCTCC NO: C2024364. The human small cell lung cancer cell line is stable in character and can be stably passaged. The human small cell lung cancer cell line highly retains genetic characteristics and biological behaviors of tumor cells of a patient, the subcutaneous tumor formation rate reaches 100%, and the human small cell lung cancer cell line is suitable for constructing animal models and researching and developing therapeutic drugs and diagnostic reagents and can be used for researching occurrence, development, metastasis and drug resistance mechanisms of small cell lung cancer.

The invention belongs to the technical field of biological medicines, and relates to application of L-ASNase in preparation of a medicine for treating bladder cancer and a kit. After the ASNS molecule is knocked down by the shRNA technology, the subcutaneous tumor-bearing growth of the immune healthy mouse can be inhibited. The knock-down ASNS has no influence on the growth of subcutaneous tumor-bearing mice in nude mice with immunodeficiency. And asparagine can promote the growth of tumors. The influence of knocking down ASNS and feeding asparagine on subcutaneous tumor-bearing growth may be dependent on an immune system. Flow cytometry discovers that knock-down of ASNS promotes recruitment of CD8 + T cells in a tumor immune microenvironment, but the knock-down of ASNS has no influence on the number of CD4 + T cells, and knock-down of the influence of ASNS on subcutaneous tumor-bearing growth may be achieved by recruitment of more CD8 + T cells and promotion of activation of the CD8 + T cells, so that the capability of killing tumor cells is achieved. In conclusion, the asparagine can promote the growth of the bladder tumor, and the growth of the bladder tumor can be inhibited through the treatment of knocking down ASNS or L-ASNase.

The invention relates to the technical field of medicines, in particular to application of a CD74 gene as a molecular marker in preparation of a bladder cancer immunotherapy curative effect prediction reagent. A mouse bladder cancer subcutaneous tumor model shows that the CD74 inhibits the occurrence and development of the bladder cancer, a bladder cancer patient with high expression of the CD74 has better response to immunotherapy, and it is indicated that the CD74 inhibits the occurrence and development of the bladder cancer and serves as a bladder cancer immunotherapy marker.

The present invention relates to the technical field of biopharmaceuticals, and provides an anti-tissue factor humanized antibody, a prepared antibody-drug conjugate, and a use. An amino acid sequence of a heavy chain of the anti-tissue factor humanized antibody is as shown in SEQ ID NO: 3, and an amino acid sequence of a light chain of the anti-tissue factor humanized antibody is as shown in SEQ ID NO: 4. The anti-tissue factor humanized antibody has high affinity to tissue factors. The present invention further provides an antibody-drug conjugate, which is obtained by coupling the anti-tissue factor humanized antibody to a cytotoxic drug. On the basis of the characteristics that the anti-tissue factor humanized antibody has high affinity and short cell endocytosis time for tumor cell strains with low-expression and high-expression tissue factors, the antibody-drug conjugate can quickly reach a tumor target to achieve cytotoxicity, and can effectively inhibit the growth of tumor cells and subcutaneous tumor growth of mice. Therefore, the antibody-drug conjugate plays an important role in cancer treatment.

The invention discloses a construction method of a humanized diffuse malignant peritoneal mesothelioma mouse model, the mouse model obtained by the construction method and application of the mouse model. The construction method comprises the following steps: constructing a DMPM subcutaneous tumor NOG mouse model by utilizing tumor blocks from human malignant peritoneal mesothelioma; the method comprises the following steps: constructing a huDMPM PBMC-NOG-dko mouse model by utilizing a tumor tissue from a DMPM subcutaneous tumor NOG mouse model; the obtained humanized diffuse malignant peritoneal mesothelioma mouse model completely retains histopathologic characteristics and molecular phenotypes of primary tumors, has a humanized immune system, and can successfully reproduce tumor-immune system interaction characteristics. The method can be used for simulating a tumor microenvironment regulation mechanism of the DMPM, evaluating drugs or therapy of the DMPM and the like.

The invention discloses an imaging window device applied to subcutaneous tumors, and belongs to the technical field of medical apparatuses and instruments. By designing the subcutaneous window comprising the imaging observation ring and the window fixing frame arranged outside the imaging observation ring in a sleeving mode, the weight of the dorsal ridge window is greatly reduced, the burden of a mouse is relieved, and great influences on physiological activities of the mouse can be effectively avoided. By arranging the fixing support detachably connected with the subcutaneous window, the subcutaneous window is fixed in the imaging platform in the imaging process, imaging artifacts caused by respiratory movement of a mouse are reduced, long-time positioning imaging can be achieved, and the imaging effect is better. The subcutaneous window is made of titanium alloy, good biocompatibility is guaranteed, long-term change of skin defect or subcutaneous tumor models can be observed through the window for a long time, blood supply cannot be damaged, a part of soft sponge can be attached to the imaging face of the window, the situation that the skin is prone to necrosis during suturing is avoided, and the real microenvironment is reflected more truly.

The invention belongs to the technical field of nano biomedicine, and particularly discloses a preparation method of a galangin-loaded bionic nano dendritic cell (DCs) vaccine and application of the galangin-loaded bionic nano dendritic cell (DCs) vaccine in ovarian cancer treatment. The inner core of the vaccine is galangin (GA)-loaded polylactic acid-glycolic acid copolymer (PLGA) nanoparticles, and the shell of the vaccine is formed by coating a DCs film carrying tumor antigens. The nano DC vaccine retains the antigen presentation function of natural DCs, and the GA loaded on the nano DC vaccine can induce tumor cells to generate immunogenic cell death. By means of the design, the vaccine can efficiently load specific tumor-associated antigens, and the homing capacity of the vaccine to lymph nodes and tumor microenvironments is remarkably enhanced. Experiments show that GA-NPs (at) DCV is used for treating subcutaneous tumor and in-situ ovarian cancer mouse models.

The invention belongs to the field of antitumor drugs, and particularly relates to a targeted 4-1BB aptamer and application of the targeted 4-1BB aptamer in preparation of antitumor drugs. A target 4-1BB nucleic acid aptamer is obtained through screening, the sequence of the target 4-1BB nucleic acid aptamer is shown as SEQ ID No.1, and the target 4-1BB nucleic acid aptamer is specifically 5 '-CACGCATAACATGTATGGACTGCTCGGGATTGCGG ATTTACATTCGTTATGCGTG-3', the sequence of the target 4-1BB nucleic acid aptamer is shown as SEQ ID No.1, and the sequence of the target 4-1BB nucleic acid aptamer is shown as SEQ ID No.1. The nucleic acid aptamer has a good application effect in preparation of anti-tumor drugs. The capacity of the aptamer for inhibiting mouse Hepa1-6 subcutaneous tumor is superior to that of mouse 4-1BB agonist antibody drugs with the same total mass. The obvious hepatotoxicity and visceral toxicity are not found; growth of mouse Hepa1-6 liver in-situ cancer can be inhibited, and the proportion of CD8 + T cells in T cells in the liver can be increased.

The invention relates to the technical field of biological medicine, in particular to a method for inducing exosomes at high temperature to play a far-isolating effect for glioma combined therapy, which comprises the following steps: step 1, putting glioma cells in a high-temperature environment for stimulation for a period of time to promote the glioma cells to release the exosomes; step 2, separating and purifying the released exosome, so as to obtain H-Exos induced at high temperature; 3, the H-Exos is applied to far-isolating effect treatment of glioma to inhibit growth, migration and invasion of far tumor cells, according to the method for combined treatment of glioma by inducing exosomes at high temperature to play the far-isolating effect, a bilateral subcutaneous tumor-bearing mouse model is established to simulate the biological characteristics of diffuse growth of clinical brain tumor, and the biological characteristics of the far-isolating effect of the glioma can be simulated to achieve the far-isolating effect of the glioma to achieve the far-isolating effect of the glioma to achieve the far-isolating effect of the glioma to achieve the far-isolating effect of the glioma. MWA is adopted to ablate tumors on one side, then exosomes generated by tumor cells MHT are creatively combined and applied, and a basic support is provided for subsequently discussing a treatment strategy that thermal therapy and exosomes are combined as glioma.

This invention discloses a combination drug of Akkermansia and an EET homologue and its uses, relating to the field of biomedical technology. Specifically, the combination drug of this invention comprises: A1) a first active ingredient, the first active ingredient comprising Akkermansia myxophilus; and A2) a second active ingredient, the second active ingredient comprising at least one of 14,15-epoxyeicosatetrienoic acid (14,15-EET) or an isomer of 14,15-epoxyeicosatetrienoic acid, a pharmaceutically acceptable salt, an ester, or a prodrug. The combination drug of this invention exhibits excellent anti-inflammatory and anti-tumor effects in LPS-induced inflammation models and LLC subcutaneous tumor models. The synergistic index SI > 1 calculated using the Bliss independent model indicates a good synergistic effect, and it can be used for the prevention, treatment, and prognostic improvement of non-small cell lung cancer.